AptamiR Therapeutics, founded as a biotechnology company, is dedicated to developing innovative treatments for obesity and related cardiometabolic disorders. The company's core mission is to create safe, effective, and convenient therapeutic agents that address unmet medical needs. AptamiR focuses on microRNA-targeted therapeutics that promote thermogenesis by converting white adipocytes into fat-burning brown-like adipocytes. This approach diverges from traditional methods by targeting subcutaneous fat cells rather than the central nervous system or intestinal absorption.

Notable affiliated people and investors include leading experts in biotechnology and venture capital firms specializing in healthcare innovations. AptamiR has achieved significant milestones in its pre-clinical development phase, showcasing promising results in treating fat accumulation, inflammation, and necrosis. The company's pioneering work in microRNA therapeutics has the potential to revolutionize obesity treatment, offering a new avenue for managing complex diseases like dyslipidemia, diabetes, and metabolic dysfunction-associated fatty liver disease.